Moe Alsumidaie: Mitapivat Challenges the Transfusion-Centric Model of Thalassaemia Care
Moe Alsumidaie, Chief Editor at The Clinical Trial Vanguard, Head of Research at CliniBiz, shared a post on LinkedIn:
“For decades, thalassaemia meant one thing for patients: a transfusion appointment every three to four weeks, year after year, for life.
That schedule just got its first real challenger.
Agios Pharmaceuticals built the ENERGIZE-T Phase 3 trial around a single question: can one twice-daily oral tablet meaningfully reduce how often patients need someone else’s blood to survive?
Across 258 patients, 48 weeks of blinded treatment, and both alpha and beta thalassaemia, the answer was yes.
The FDA agreed, approving mitapivat in December 2025 as the first oral treatment for anemia in adults with beta-thalassaemia and the first drug approval of any kind for adults with alpha-thalassaemia.
The part the headline misses: the trial’s design is the real story.
Agios chose transfusion burden reduction as the primary endpoint, not hemoglobin response, not a surrogate.
That is a harder target, and the FDA accepting it signals something bigger for the field.
Any sponsor now running a chronic transfusion program will face a benchmark of 258 patients and 48 weeks of clean data.
A shorter trial will need a pre-negotiated justification.
The bar moved on December 23, 2025, and it is not moving back.
The economics make this urgent.
Annual healthcare costs for transfusion-dependent thalassaemia patients in the U.S. run over 137,000 dollars per patient.
A therapy that compresses transfusion frequency compresses those cost curves for decades.
Are we building enough health economics evidence into rare disease Phase 3 designs from the start, or are we still treating it as a post-approval problem?”
Stay updated with Hemostasis Today.
-
Sep 15, 2026, 14:28Jonathan Douxfils: The Emerging Role of Estetrol in Menopausal Hormone Therapy
-
Sep 15, 2026, 14:19Mohammad Salar Amoli: The Coagulation Laboratory Approach to Hemophilia A
-
Sep 15, 2026, 14:09Lydia Pecker: A Call for Blood Donors for Sickle Cell Patients
-
Sep 15, 2026, 13:50Richard Godin: Challenges in Diagnosing Homozygous Familial Hypercholesterolemia
-
Sep 15, 2026, 13:42Sujan Sivasubramaniyam: Three Decades of Progress for Children with Haemophilia in Morocco
-
Sep 15, 2026, 13:31Mohammed Alkhani: Challenging the Conventional Approach to Paget-Schroetter Syndrome
-
Sep 15, 2026, 13:29Shadi Tabibian: Three Years of Progress Toward Life Beyond Hemophilia
-
Sep 15, 2026, 13:24Randall Curtis: Very Rewarding Week as a Co-Author, With a New Article in Production
-
Sep 15, 2026, 12:55Christopher Cannon: Calcium Scoring for Better Cardiovascular Risk Assessment